1887

Abstract

MmpL3 is a promising target for novel anti-tubercular agents, with numerous compound series identified as MmpL3 inhibitors. Despite this, there is an incomplete understanding of MmpL3 function. Here we show that MmpL3 mutant strains had an altered cell wall hydrophobicity, disrupted membrane potential and growth defects in liquid media. Compensatory mutations that restored normal growth also returned membrane potential to wild-type. MmpL3 mutant strains were resistant to two anti-tubercular agents, SQ109 and AU1235, but were more sensitive to rifampicin, erythromycin and ampicillin. Exposure of to AU1235 affected the cell wall composition and increased the potency of rifampicin. However, MmpL3 mutants did not prevent the dissipation of membrane potential following exposure to SQ109. These results demonstrate that in MmpL3 contributes to a number of important phenotypes such as membrane potential, cell wall composition, antibiotic susceptibility and fitness.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.000498
2017-07-01
2019-12-07
Loading full text...

Full text loading...

/deliver/fulltext/micro/163/7/1065.html?itemId=/content/journal/micro/10.1099/mic.0.000498&mimeType=html&fmt=ahah

References

  1. Domenech P, Reed MB, Barry CE. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 2005;73:3492–3501 [CrossRef][PubMed]
    [Google Scholar]
  2. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 2012;8:334–341 [CrossRef][PubMed]
    [Google Scholar]
  3. Li W, Obregón-Henao A, Wallach JB, North EJ, Lee RE et al. Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3. Antimicrob Agents Chemother 2016;60:5198–5207 [CrossRef][PubMed]
    [Google Scholar]
  4. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 2012;56:324–331 [CrossRef][PubMed]
    [Google Scholar]
  5. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012;56:1797–1809 [CrossRef][PubMed]
    [Google Scholar]
  6. Stec J, Onajole OK, Lun S, Guo H, Merenbloom B et al. Indole-2-carboxamide-based MmpL3 inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection. J Med Chem 2016;59:6232–6247 [CrossRef][PubMed]
    [Google Scholar]
  7. Remuiñán MJ, Pérez-Herrán E, Rullás J, Alemparte C, Martínez-Hoyos M et al. Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One 2013;8:e60933 [CrossRef][PubMed]
    [Google Scholar]
  8. Foss MH, Pou S, Davidson PM, Dunaj JL, Winter RW et al. Diphenylether-modified 1,2-diamines with improved drug properties for development against Mycobacterium tuberculosis. ACS Infect Dis 2016;2:500–508 [CrossRef][PubMed]
    [Google Scholar]
  9. Belardinelli JM, Yazidi A, Yang L, Fabre L, Li W et al. Structure-function profile of MmpL3, the essential mycolic acid transporter from Mycobacterium tuberculosis. ACS Infect Dis 2016;2:702–713 [CrossRef][PubMed]
    [Google Scholar]
  10. Lun S, Guo H, Onajole OK, Pieroni M, Gunosewoyo H et al. Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nat Commun 2013;4:2907 [CrossRef][PubMed]
    [Google Scholar]
  11. Gagneux S, Long CD, Small PM, van T, Schoolnik GK et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006;312:1944–1946 [CrossRef][PubMed]
    [Google Scholar]
  12. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat Rev Microbiol 2010;8:260–271 [CrossRef][PubMed]
    [Google Scholar]
  13. Tempelaars MH, Rodrigues S, Abee T. Comparative analysis of antimicrobial activities of valinomycin and cereulide, the Bacillus cereus emetic toxin. Appl Environ Microbiol 2011;77:2755–2762 [CrossRef][PubMed]
    [Google Scholar]
  14. Gentry DR, Wilding I, Johnson JM, Chen D, Remlinger K et al. A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential. J Microbiol Methods 2010;83:254–256 [CrossRef][PubMed]
    [Google Scholar]
  15. Li W, Upadhyay A, Fontes FL, North EJ, Wang Y et al. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:6413–6423 [CrossRef][PubMed]
    [Google Scholar]
  16. Schreuder LJ, Carroll P, Muwanguzi-Karugaba J, Kokoczka R, Brown AC et al. Mycobacterium tuberculosis H37Rv has a single nucleotide polymorphism in PhoR which affects cell wall hydrophobicity and gene expression. Microbiology 2015;161:765–773 [CrossRef][PubMed]
    [Google Scholar]
  17. Rosenberg M. Microbial adhesion to hydrocarbons: twenty-five years of doing MATH. FEMS Microbiol Lett 2006;262:129–134 [CrossRef][PubMed]
    [Google Scholar]
  18. Odds FC. Antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003;52:1 [CrossRef][PubMed]
    [Google Scholar]
  19. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006;58:332–337 [CrossRef][PubMed]
    [Google Scholar]
  20. Li W, Sanchez-Hidalgo A, Jones V, de Moura VC, North EJ et al. Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro. Antimicrob Agents Chemother 2017;61:e02399-16 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.000498
Loading
/content/journal/micro/10.1099/mic.0.000498
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error